^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TGF-β R2 kinase inhibitor

    Related drugs:
    5d
    Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701)
    12d
    MA-CRC-II-018: Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=48, Recruiting, Hong Qiu
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    retlirafusp alfa (SHR-1701)
    18d
    SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • retlirafusp alfa (SHR-1701)
    24d
    SHARP: SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC (clinicaltrials.gov)
    P2, N=66, Recruiting, Fudan University
    New P2 trial
    |
    retlirafusp alfa (SHR-1701)
    1m
    Immunosuppressive-responsive hydrogel for self-regulated drug release and tumor microenvironment reprogramming. (PubMed, J Control Release)
    To address this, an intelligent and injectable thermo-responsive hydrogel delivery system (LY@CNSG) constructed from cyclodextrin nanosponges and poly(N-isopropylacrylamide) was developed, in response to immunosuppressive prostaglandin E2 (PGE2) levels for autonomously controlling the release of LY2109761 (LY, a TGF-β inhibitor) based on competitive host-guest interaction. In triple-negative breast cancer models, photodynamic therapy combined with LY@CNSG significantly inhibited tumor growth and lung metastasis while enhancing antitumor immune activity. Furthermore, by integrating nitric oxide (NO)-responsive fluorescent probes, we created an integrated hydrogel platform, CYNH2-LY@CNSG, for simultaneous immunomodulator delivery and immune signaling molecule monitoring, providing a novel insight for biomarker monitoring and a more precise immunotherapy paradigm.
    Journal • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    LY2109761
    1m
    A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (clinicaltrials.gov)
    P3, N=700, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • 5-fluorouracil • leucovorin calcium • INCA33890
    2ms
    SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    paclitaxel • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • retlirafusp alfa (SHR-1701)
    2ms
    A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=104, Not yet recruiting, Qinglei Gao
    New P2 trial
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    AiRuiYi (fluzoparib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020)
    2ms
    Single-cell and immune-context integration identifies basement-membrane/metastasis signatures that sharpen bladder-cancer diagnosis and prognosis. (PubMed, Discov Oncol)
    The MBRG-based model effectively predicts BLCA prognosis, integrates mechanisms of basement membrane remodeling, EMT, and immune suppression, and identifies DDR2 and SERPINF1 in CAFs as potential targets for personalized therapy.
    Journal • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • DDR2 (Discoidin domain receptor 2) • SLIT2 (Slit Guidance Ligand 2)
    |
    dasatinib • LY2109761 • WNT974
    3ms
    PD1/TGFβ In Combination With EZH2 And Chemotherapy For First - Line Treatment Of Gastric Cancer (clinicaltrials.gov)
    P2, N=36, Recruiting, The First Affiliated Hospital of Zhengzhou University
    New P2 trial
    |
    capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554)
    3ms
    A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma. (PubMed, Signal Transduct Target Ther)
    The interactions within tumor microenvironment were involved disease progression. Overall, first-line SHR-1701 plus AG showed promising anti-tumor activity and controllable safety in advanced or metastatic pancreatic ductal adenocarcinoma, and features of patients more likely to benefit from the combination were drawn.
    P1/2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1) • CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • retlirafusp alfa (SHR-1701)
    3ms
    A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (clinicaltrials.gov)
    P3, N=700, Not yet recruiting, Incyte Corporation
    New P3 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • leucovorin calcium • INCA33890